Chemistry:CUMYL-PEGACLONE
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C25H28N2O |
| Molar mass | 372.512 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug.[2][3][4][5][6][7] The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.[8][9][10]
Legal status
Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.[11]
In the United States, the DEA has temporarily placed CUMYL-PEGACLONE into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file for permanent placement the temporary Schedule I order will expire on December 12th, 2025.[12]
See also
- 5F-CUMYL-PEGACLONE
- CUMYL-CB-MEGACLONE
- CUMYL-CH-MEGACLONE
- CUMYL-BC-HPMEGACLONE-221
- CUMYL-PINACA
- CUMYL-5F-P7AICA
- UR-12
References
- ↑ "Substance Details CUMYL-PEGACLONE". https://www.unodc.org/LSS/Substance/Details/d8783925-3233-41a9-b9aa-ddeb60242828.
- ↑ "Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017". Forensic Science International 277: 51–58. August 2017. doi:10.1016/j.forsciint.2017.05.019. PMID 28601726.
- ↑ "Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE". Drug Testing and Analysis 10 (3): 597–603. July 2017. doi:10.1002/dta.2237. PMID 28670781.
- ↑ "Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples". Drug Testing and Analysis 10 (5): 886–891. January 2018. doi:10.1002/dta.2352. PMID 29314750.
- ↑ "Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?". Drug Testing and Analysis 11 (2): 347–349. February 2019. doi:10.1002/dta.2545. PMID 30468574.
- ↑ "In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration". Drug Testing and Analysis 12 (9): 1336–1343. September 2020. doi:10.1002/dta.2870. PMID 32490586. https://biblio.ugent.be/publication/8687072.
- ↑ "Emergence of Cumyl-PEGACLONE-related fatalities in the Northern Territory of Australia". Forensic Science, Medicine, and Pathology 17 (1): 3–9. November 2020. doi:10.1007/s12024-020-00334-0. PMID 33185835.
- ↑ Leftheris K, Zhao, R, Chen BC, Kiener P, Wu H, Pandit C, Chennagiri R, Wrobleski S, Chen P, Hynes j, Longphre M, Norris D, Spergel S, Tokarski J, "Cannabinoid Receptor Modulators, Their Processes of Preparation, and Use of Cannabinoid Receptor Modulators in Treating Respiratory and Non-Respiratory Diseases", WO patent application 2001058869, published 16 August 2001, assigned to Bristol-Myers Squibb Company
- ↑ "Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties". Journal of Medicinal Chemistry 46 (11): 2110–6. May 2003. doi:10.1021/jm020329q. PMID 12747783.
- ↑ "Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists". Drug Testing and Analysis 12 (3): 297–315. March 2020. doi:10.1002/dta.2752. PMID 31854124.
- ↑ "Sexton nya ämnen klassas som narkotika eller hälsofarlig vara" (in sv). Folkhälsomyndigheten. 18 January 2019. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/januari/sexton-nya-amnen-klassas-som-narkotika-eller-halsofarlig-vara/.
- ↑ "Federal Register :: Request Access". https://www.federalregister.gov/documents/2023/12/12/2023-27243/schedules-of-controlled-substances-temporary-placement-of-mdmb-4en-pinaca-4f-mdmb-butica.
 |  |
